SORLA Protein Reduced Brain Damage in Mice Study
Researchers found that increasing SORLA protein levels suppressed harmful tau accumulation in mouse brain models.
Updated on Sept. 19, 2026 in Alzheimer’s
Live Poll
Do you believe current protein-based research is likely to yield successful Alzheimer's treatments soon?
A study published on July 17, 2026, in Science Advances revealed that elevating SORLA protein levels reduced tau damage and brain atrophy in mice. The findings suggest that this protein could be a key target in addressing tau-related dementia.
Why it matters
While SORLA is traditionally linked to amyloid-beta, this research indicates it also plays a significant role in mitigating tau tangles. Targeting this protein may offer a new pathway for developing dementia treatments.
The study utilized a data collection period spanning 15 to 20 years to investigate the protein. Researchers confirmed that increased SORLA levels successfully suppressed tau hyperphosphorylation and preserved synapses in mouse brains.
The players
Sanford Burnham Prebys
This is a nonprofit medical research institute located in San Diego that focuses on basic and translational research.
Science Advances
This is a peer-reviewed, open-access scientific journal published by the American Association for the Advancement of Science.
The details
Sanford Burnham Prebys researchers genetically modified mice to produce extra human SORLA, resulting in reduced brain atrophy and tau tangles. Conversely, the absence of the Sorl1 gene was found to exacerbate brain damage and increase levels of plexin-B receptors.
Timeline
The study was published in Science Advances on July 17, 2026.
Deeper Dive
This study advances the SORLA protein research framework by demonstrating its impact on tau pathology beyond amyloid-beta regulation. The findings bridge gaps between protein-trafficking research and the development of tau-related dementia therapeutics.
This research provides a new potential target for future dementia therapies, though it is currently limited to preclinical mouse models. Patients may eventually see new drug classes emerge that focus on plexin-B receptors or SORLA protein pathways.
The takeaway
Understanding how SORLA protects against tau accumulation provides a clearer target for neurodegenerative research. Continued investigation into plexin-B receptor modulation could lead to the next generation of treatments for memory-related diseases.
Further reading
For more on evolving research, visit our Alzheimer’s section.
More information
Read the full Science Advances study publication for complete methodology.
Live Poll
Do you believe current protein-based research is likely to yield successful Alzheimer's treatments soon?
